News

CMN Weekly (18 March 2022) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Mar. 18, 2022

Top picks

Research

Clinical trials

Industry

Financial reports - all with updates on CRISPR/gene editing programmes

Detection

Reviews

Opinions and perspectives

News from CRISPR Medicine News

  • Monday's feature article reported how researchers at Jennifer Doudna's lab had used DNA origami as a new CRISPR delivery system. Folding DNA into compact structures allows for efficient integration of large genes, and this might lead to new therapies for genetic diseases with many disease-causing mutations and deletions.
  • This week's clinical update included news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation from the FDA to treat advanced kidney cancer. In addition, Intellia Therapeutics' NTLA-5001 has been granted Orphan Drug Designation to treat acute myeloid leukaemia.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (18 March 2022) - Your Weekly CRISPR Medicine News
Search your next CRISPR job here...
Search your next CRISPR job here...
CLINICAL TRIALS
Solid Tumors (NCT03970382)
Sponsors:
PACT Pharma, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT05442346)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine